WEBULL
WebtradeDownload

What Tempus AI (TEM)'s Military Cancer Care Partnership Means For Shareholders

Simply Wall St · 2d ago
  • SOTERIA Precision Medicine Foundation recently disclosed a collaboration with Tempus AI to provide genomic sequencing, AI-driven cancer treatment insights, and precision oncology navigation for active-duty U.S. military personnel and veterans.
  • By integrating a defined military and veteran cohort into Tempus AI's data and diagnostics platform, this partnership deepens the firm’s real-world evidence base and can reinforce demand for its precision oncology services across both testing and data products.
  • We will now look at how Tempus AI’s expanded precision oncology role with SOTERIA affects the broader long term investment narrative.

Scan how Tempus AI’s military-focused precision oncology push compares with other specialized healthcare AI players by reviewing the hand-picked 36 healthcare AI stocks shaping this corner of the market.

Tempus AI Investment Narrative Recap

To own Tempus AI, you need to believe the healthcare data flywheel that QuanD, an investor in the Simply Wall St Community, describes keeps compounding. Diagnostics feeds more multimodal records into the platform, which can support the Data and Applications segment. The SOTERIA partnership fits that view but does not obviously change the near term story on its own.

Right now, the key near term catalyst is execution on revenue and the path toward consistent profitability. The latest military collaboration may support testing volume and data depth over time, while the main risk still sits with ongoing losses, higher risk funding, valuation pressure and a volatile share price if expectations slip.

The third quarter update on 2 November 2026 looks most relevant. Tempus AI reported quarterly sales of US$303.47m and total revenue of US$411.54m, with the quarterly net loss narrowing to US$14.85m. For the first nine months of 2026, revenue reached US$1.142b and the loss for that period was US$135.13m.

Management also raised full year 2026 revenue guidance to a range of US$1.60b to US$1.605b. This aligns with QuanD’s focus on the platform’s data driven growth potential. Hitting or missing that range now sits front and center as an operational catalyst, while any stumble could matter for a stock already flagged as expensive on P/S multiples.

QuanD’s narrative reaches a fair value of US$75.68 for Tempus AI by assuming revenue compounds at 15% a year, the business reaches a 25% profit margin in future, and the resulting earnings stream supports that valuation, according to Simply Wall St’s Future Multiple Valuator framework.

Uncover why Tempus AI's fair value indicates a 5% potential downside to its current price, which leaves little room for error.

NasdaqGS:TEM 1-Year Stock Price Chart
NasdaqGS:TEM 1-Year Stock Price Chart

Exploring Other Perspectives

Some of the most optimistic analysts frame Tempus AI’s collaboration with SOTERIA through a different lens. They focus on the revenue trajectory. Before this news, the bullish group was already modeling about 26.7% annual top line growth and revenue of roughly US$2.9b by 2029. That view assumes earnings of about US$472.8m and a P/E near 50x. If you prefer that narrative, you are effectively betting the new military data stream could strengthen an already ambitious path, or, if it disappoints, force those projections to be reset. It is worth comparing those upbeat assumptions with other opinions before deciding which story you find more convincing.

Explore 4 other Tempus AI fair value estimates, including one that suggests up to 27% upside from the current price.

Reach Your Own Conclusion

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Ideas Beyond Tempus AI?

Once you have formed a view on Tempus AI, it can help to widen the lens and compare it with other potential opportunities that suit different risk and income preferences.